Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Research & Development (2016 - 2026)

Protara Therapeutics' Research & Development history spans 14 years, with the latest figure at $13.6 million for Q1 2026.

  • Quarterly Research & Development rose 48.25% to $13.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $47.0 million through Mar 2026, up 42.12% year-over-year, with the annual reading at $42.6 million for FY2025, 34.47% up from the prior year.
  • Research & Development came in at $13.6 million for Q1 2026, up from $13.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $13.6 million in Q1 2026 to a low of $3.1 million in Q2 2022.
  • The 5-year median for Research & Development is $7.2 million (2023), against an average of $7.6 million.
  • Year-over-year, Research & Development tumbled 47.61% in 2022 and then skyrocketed 134.99% in 2023.
  • Protara Therapeutics' Research & Development stood at $5.0 million in 2022, then rose by 27.9% to $6.4 million in 2023, then skyrocketed by 48.86% to $9.5 million in 2024, then soared by 38.16% to $13.1 million in 2025, then increased by 3.34% to $13.6 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Research & Development are $13.6 million (Q1 2026), $13.1 million (Q4 2025), and $9.6 million (Q3 2025).